Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Furthermore, alongside the increasing prevalence of related cardiometabolic diseases such as diabetes, obesity and chronic kidney disease (CKD), the number of people with HF has increased to around 64 million globally, amongst whom most are also living with type 2 diabetes or obesity ( Within the past 2 decades, glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as effective agents to improve glycaemic control in type 2 diabetes and to reduce body weight in people with overweight or obesity (Mller et al., 2019
89 ShaoS
Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion from pancreatic -cells in hyperglycemic conditions but is cleaved by dipeptidyl peptidase-4 (DPP-4), an adipokine released in excessive amounts by adipose tissue in patients with obesity [85, 86]
[1] In the brain, the same receptor lowers appetite and food intake
